iOrganBio, Inc

iOrganBio, Inc. is a biotechnology company based in Chapel Hill, US, focused on developing advanced biotechnological solutions, particularly in human cell and organoid manufacturing through its innovative CellForge™ Platform. Founded in 2024, iOrganBio, Inc. operates from Chapel Hill, US, specializing in biotechnological innovations.

The company has not undergone any significant pivots or structural changes since its inception. iOrganBio recently secured USD 2. 00 mn in a funding round led by First Star Ventures and supported by other investors including IndieBio, Cape Fear BioCapital, 2ndF, Terasaki Institute, and Alix Ventures. This funding will be allocated to enhance their CellForge™ Platform.

The company has raised a total of USD 2. 00 mn across two deals, with the most recent funding round completed on October 29, 2025. iOrganBio (iOB) specializes in advanced biotechnological solutions, primarily through its flagship CellForge™ Platform, which revolutionizes the creation and manufacturing of human cells and organoids. The platform integrates AI prediction, biological sensing, and automated 3D incubation to streamline complex cellular science into a programmable and scalable process.

The core offerings focus on providing reliable, ready-to-use cells tailored to specific research and therapeutic needs, thereby addressing challenges in in vitro modeling and cell therapies. The company’s CellForge™ technology facilitates the development of a wide range of cell types, enhancing accessibility to advanced models and therapies. iOrganBio serves a diverse client base, including researchers, biotech firms, and pharmaceutical companies globally, particularly in North America and Europe, enabling them to accelerate innovations in treatments and diagnostics. iOrganBio's revenue model is structured around partnerships and client contracts, primarily within the B2B sector, where the company provides tailored cell products and services to research institutions and biotech companies.

Transactions typically involve agreements that outline the specifications of cell products derived from the CellForge™ Platform, ensuring alignment with client requirements. Pricing structures may vary based on the complexity and scale of cell production; however, specific figures for individual services are not disclosed. The company anticipates that its unique offerings, particularly the AI-enhanced capabilities of CellForge™, will drive sustained demand, supporting both clinical and commercial applications in the expanding biotechnology landscape. iOrganBio plans to advance its CellForge platform to support drug discovery, manufacturing, and cell therapies.

The recent funding of USD 2. 00 mn will be utilized to accelerate the development of new features within the platform. The company aims to expand its market reach into additional regions, including Europe and Asia, by 2026, enhancing its ability to serve a broader range of clients in the biotechnology sector.